Objectives. Autoantibodies targeting ubiquitously expressed nuclear antigens can be identified in most patients with SSc. Cytoplasmic autoantibodies (in otherwise ANA-negative sera) targeting eukaryotic initiation factor-2B (anti-eIF2B) have recently been identified in SSc with clinical associations to dcSSc disease and interstitial lung disease (ILD), although the majority of samples originated from a tertiary SSc-ILD centre. We investigated the prevalence and clinical associations of recently described SSc-specific (including anti-eIF2B) and other cytoplasmic autoantibodies in ANA-negative sera obtained from a large representative SSc cohort.
Introduction
Identification of autoantibodies targeting intracellular antigens helps support diagnosis and predict disease course in SSc [1] . The majority of SSc-specific and SSc-associated autoantibodies target nuclear proteins and their presence is sometimes suggested by characteristic ANA staining patterns on IIF. Commercially available addressable laser bead immunoassays, ELISA and line immunoassays identify the antigen target for the majority of ANA-positive SSc samples following IIF. Radiolabelled protein immunoprecipitation (IPP) is the gold standard for confirming the presence of autoantibodies to intracellular antigens in SSc. Previous registry analysis has detected ANA on IIF in 98.3% of patients with SSc, within whom SSc-specific or SSc-associated autoantibodies were characterized in 92.2% using commercially available methods (addressable laser bead immunoassays, ELISA and line immunoassays), rising to 96.5% following IPP [2] .
Antibodies targeting eukaryotic initiation factor 2B (anti-eIF2B) were recently identified (using IPP) in seven patients with SSc, each of whom was negative for existing SSc-specific autoantibodies and had a fine cytoplasmic speckle (FCS) on IIF but no direct nuclear staining (i.e. ANA negative) [3] . Anti-eIF2B antibodies were associated with dcSSc and interstitial lung disease (ILD), although selection bias was likely as the majority of samples were obtained from a large tertiary SSc-ILD centre. The principal objectives of the present study was to use IPP to investigate the prevalence and clinical associations of anti-eIF2B antibodies (and additional CTD-specific autoantibodies) in ANA-negative samples obtained from a larger, more representative cohort of SSc [4] .
Methods

Study population
Samples were obtained from the Scleroderma Family Registry and DNA Repository that has enrolled patients from 11 US scleroderma centres and participating Canadian Scleroderma Research Group sites as previously described [4, 5] . IRB approval was obtained at all participating sites and all participants provided informed written consent [4, 5] . The study pre-dated the 2013 ACR/ EULAR classification criteria for SSc but all patients fulfilled the 1980 ARA preliminary classification criteria for SSc and/or had three or more of the five clinical features of calcinosis, Raynaud's phenomenon, oesophageal dysfunction, sclerodactyly and telangiectasias syndrome, with sclerodactyly being mandatory [6, 7] , ensuring a representative scleroderma patient cohort.
ANA-negative samples
To be considered ANA-negative in the earlier study [4] , IIF was negative on HEp-2 cells (titre 1:80, assessed by a single investigator), passive immunodiffusion (ID) using commercial assays for anti-Scl70, anti-Ro60, anti-La (Inova Diagnostics, San Diego, CA, USA) and ELISA for anti-RNA polymerase III (MBL Co. Ltd, Nagoya, Japan).
Laboratory investigations ANA-negative samples (with sufficient available serum) underwent repeat IIF using HEp-2 cells and fluoresceinlabelled anti-human IgG (Inova Diagnostics), with patterns assessed at titre 1:40 by a single investigator (H.L.) followed by IPP as previously described [3] . Sera that immunoprecipitated a 30 kDa band underwent immunodepletion to confirm antigen specificity for eIF2B as previously described [3] .
Sera that immunoprecipitated a doublet (molecular masses $50 kDa) were analysed for suspected antiRuvBL1/2 antibodies. IPP was completed using either 40 ml sera or 20 ml polyclonal rabbit anti-RuvBL1, 2 mg protein-A-Sepharose and 5 mM suberic-acid-bis-sodium. Beads were incubated with 1 ml K562 extract (prepared from 28 Â 10 6 cells/ml) for 3 h and re-suspended in sample buffer. Immunoprecipitates were fractionated by 10% SDSPAGE, transferred to nitrocellulose and probed with anti-RuvBL1 (1:500 dilution) for 90 min. Bands were detected using an alkaline phosphatase-conjugated goat anti-rabbit IgG (1:0000 dilution) and 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) in conjunction with nitro blue tetrazolium (NBT) substrate solution (all chemicals obtained from Sigma-Aldrich, Gillingham, UK).
Assessment of clinical associations
Definitions of disease-associated clinical features for patients enrolled in the Scleroderma Family Registry and DNA Repository have been described previously [4] . In brief, disease subtype (lcSSc vs dcSSc) was based on the physician-assessed extent of skin involvement at enrolment [7] . There were no study-mandated procedures and all investigations were requested at the discretion of the treating physician. SSc-ILD was defined as the presence of honeycombing, increased interstitial markings or ground glass opacity on either chest radiograph or chest CT and/or the presence of restrictive lung disease indicative of ILD determined by a forced vital capacity of < 70% predicted. Within this cohort, pulmonary function test results were available for analysis in 80.8% of cases and chest imaging using radiograph, standard CT or highresolution CT (HRCT) was available in 23.3, 12.3 and 23.2% of patients, respectively. Arthropathy was defined as documented synovitis and/or joint pain.
Results
Of 3249 patients enrolled in the study, 208 (6.4%) were initially considered ANA negative. Sufficient serum was available for 128 ANA-negative samples (Fig. 1A) . Repeat IIF remained negative for nuclear staining in 46 samples (36%), although 25 of these samples exhibited a cytoplasmic speckle on IIF (6 coarse and 19 FCS), with IPP bands present in 21/25 subjects. Seven subjects with a FCS exhibiting a 30 kDA band on IPP were subsequently confirmed as positive for anti-eIF2B antibodies on immunodepletion ( and/or FVC<70% predicted (only one patient had FVC<70% predicted without imaging evidence of ILD). B: black; CAL: calcinosis; DU/DP: digital ulceration/digital pitting; FCS: fine cytoplasmic speckle; F: female; FS NS: fine speckle nucleolar sparing; GORD: gastro-oesophageal reflux disease; ILD: interstitial lung disease; M: male; MAL: malabsorption; N/A: not available; Neg: negative; PAH: pulmonary artery hypertension; SRC: scleroderma renal crisis; TEL: telangiectasia; W: white Caucasian.
and anti-Zo (n = 1) antibodies (Fig. 1C) . The remaining seven subjects exhibited unknown bands (no apparent commonality). The remaining four ANA negative subjects with a cytoplasmic speckle on repeat testing had no visible bands on IPP. Within the 21 patients that remained ANA negative on repeat IIF without a cytoplasmic speckle, IPP identified one subject with anti-Ro antibodies and another subject with anti-RuvBL1/2 antibodies (Table 1 and Fig. 1C) .
A combination of nuclear staining patterns were present in the remaining 82 samples (16 nucleolar, 10 homogeneous, 26 fine speckle and 30 coarse speckle). Within this group, IPP identified established SSc-specific and SSc-associated autoantibodies in 21 samples (16.4%), including anti-RNA Pol I/III (n = 9, two of which also exhibited anti-Ro), anti-U1RNP (n = 3), anti-topoisomerase (n = 1), anti-U3-RNP (n = 1) and anti-Ro (n = 4, one of which contained anti-La and one with concomitant antimitochondrial antibodies). Two additional samples were positive for anti-eIF2B antibodies (each of which had a fine speckled nucleolar sparing nuclear-staining pattern alongside a FCS). Anti-RuvBL1/2 antibodies were identified in a sample with a fine speckled nucleolar sparing nuclear staining pattern on IIF. Of the remaining 61 patients with anti-nuclear staining on repeat IIF, unknown bands were identified in 30 subjects (no commonality), whereas 31 subjects had no visible IPP bands.
Across the sample cohort (n = 128), antibodies with a known antigen target were present in 37 subjects (28.9%), unknown bands in isolation were identified in 46 subjects (35.9%), rising to 73 (57%) when unknown bands were identified in conjunction with a known antibody. No visible bands were identified on IPP in 45 samples (35.2%).
The IIF pattern and clinical features of the nine antieIF2B positive patients are summarized in Table 1 . The majority of patients had dcSSc (8/9, 89%), although the mean modified Rodnan Skin Score (documented in 7/9) was only 17.7 units. All patients with previous chest imaging (7/9, 78%) had radiographic evidence of SSc-ILD on CT (6/6, 100%) and/or plain radiograph (4/4, 100%). Pulmonary function tests (documented in 7/9, 78%) revealed a mean forced vital capacity of 63.4% predicted and mean diffusing capacity of the lungs for carbon monoxide (DLco) of 64.3% predicted. The prevalence of digital ulcers (2/9) and pulmonary arterial hypertension (1/9) was low. Joint involvement was common (6/7 were documented) and two patients with anti-eIF2B antibodies were considered to have an overlap syndrome with RA. Despite the major association with myositis-spectrum disorders, all seven patients with positive anti-synthetase antibodies fulfilled 2013 ACR/EULAR classification criteria for SSc [8] and only one patient had documented evidence of myopathy (not considered part of a PM overlap). One patient with anti-RuvBL1/2 had dcSSc complicated overlap features of PM, whereas the second had lcSSc with overlap features of SS (Table 1) .
Discussion
This is the largest study of ANA-negative SSc to incorporate IPP undertaken to date. We have confirmed the previously reported clinical association of anti-eIF2B autoantibodies with dcSSc and SSc-ILD in a larger, more representative SSc patient population. Our earlier study suggested a high prevalence of overlap syndrome in anti-eIF2B positive patients with SSc but only 2/9 were classified as such in this study (both RA). Previous work suggests anti-eIF2B antibodies are specific to SSc (not found in healthy controls or patients with other forms of autoimmune rheumatic disease) and are not found in SSc patients with positive nuclear staining on IIF [3] . Our findings suggest $75% (14/19) of SSc patients with a negative anti-nuclear stain but a positive FCS pattern on IIF carry either anti-eIF2B antibodies or antisynthetase antibodies (but never in combination).
Autoantibodies targeting cytoplasmic tRNA synthetases have previously been described in SSc [2, 9] highlighting the considerable overlap in clinical phenotype that exists between the SSc and myositis-spectrum disorders. Antisynthetase antibody positive patients in this study fulfilled contemporary classification criteria for SSc [8] , challenging the validity of the term 'myositis-specific autoantibodies' to describe anti-synthetase antibodies. None of the anti-synthetase antibody positive patients had been formally classified as overlap syndrome with PM (or other rheumatic diseases), although relevant clinical features such as mechanics hands were not routinely captured in this study of SSc. A myopathy was recorded in the patient with anti-OJ (Table 1) . This is the second study to report the clinical features of anti-RuvBL1/2 antibodies in SSc and our findings strengthen the previously reported association with SSc-overlap syndromes (present in $60% of original case series) [10] . RuvBL1/2 is an important modulator of transcriptional activation and protein assembly (including certain RNPs and RNA polymerase) and essential for cell proliferation [11] . It is mainly localized in the nucleus but can be present in the cytoplasm. Anti-RuvBL1/2 antibodies have also been reported in a case of PM with morphoea [12] . This study was not appropriately designed to evaluate the prevalence of anti-eIF2B and antiRuvBL1/2 autoantibodies in SSc but previous estimates have suggested rates of 1.8% and 1.7%, respectively [3, 10] .
The identification of anti-nuclear staining patterns on repeat HEp2 IIF testing is not unexpected, in view of differences in screening titre, the use of non-standardized reagents between laboratories and subjective thresholds applied to reporting staining patterns. We deliberately applied a low threshold for reporting IIF staining patterns to maximize the sensitivity for detecting antibodies within this sample cohort. Established SSc-specific and SSc-associated autoantibodies (excluding the more recently described anti-eIF2B and anti-RuvBL1/2 antibodies) were present in 14% of this previously designated 'ANA-negative' cohort, which had not been identified on earlier screening investigations including immunodiffusion and ELISA. Some antibody specificities, for example anti-U3-RNP, are not routinely identified using these techniques, but others, for example anti-RNA Pol III, are normally captured. Identification of autoantibodies using IPP in sera previously negative to alternative immunoassays capable of identifying such specificities has previously been demonstrated and highlights the variable sensitivity of different methods of antibody detection compared with the gold standard of IPP [2, 9] . The emergence and refinement of relatively inexpensive commercially available line immunoassays for SSc-specific and myositis-specific autoantibodies will improve the sensitivity of autoantibody assessment in future studies, potentially reducing reliance on more specialist techniques such as IPP. Unknown bands on IPP are not uncommon and our preliminary analysis for commonality of the bands has not yet identified any novel antigen targets in SSc using these samples.
Direct comparison between the significance of ANA negative SSc in the present study and previous registry analyses is challenging due to differences in disease classification, definitions surrounding 'ANA negativity' and immunoassay methods applied. In the present study, the absence of nuclear/cytoplasmic staining on IIF and the absence of detectable known autoantibodies using IPP (including newer antibodies such as anti-eIF2B) occurred in only 19 samples (from 3249 patients, 0.58%). This is lower than an estimate of 1.7% of SSc patients being autoantibody negative in an earlier smaller study applying similar investigative techniques [2] . The term autoantibody negative in this context might be misleading as the investigative techniques cannot fully exclude the presence of antibodies targeting cellular (e.g. anti-endothelial cell) or cell-surface (e.g. anti-PDGF receptor) antigens. Our findings indicate that SSc is very rare in patients without nuclear/cytoplasmic staining on IIF, in whom a detectable antibody specificity using IPP cannot be identified. This study also highlights the value of an extended array of investigative techniques for autoantibody detection when evaluating SSc-spectrum disorders (particularly when IIF reveals a fine cytoplasmic speckle without nuclear staining).
